Arcus Biosciences Inc (NYSE: RCUS) has climbed $1.04 (5.66%) and sits at $19.38, as of 12:07:44 est on May 13.

886,060 shares have exchanged hands.

The Company has decreased 19.42% over the last 5 days and shares fell 40.23% over the last 30 days.

Arcus expects its next earnings on 2022-08-04.

For technical charts, analysis, and more on Arcus visit the company profile.

About Arcus Biosciences Inc

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1- 1.

To get more information on Arcus Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Arcus Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold

The Best Laid Plans of Mice and Men — Part I

Bumble Beats First Quarter Estimates, Has Over 3 Million Paying Users

Squarespace Beats Revenue Estimates With Record Q1

BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million

How To Trade in a Bearish Market

AbbVie and Teva Weighing $5 Billion Opioid Lawsuit Settlement